| Catalog No. | HB996016 |
| Brand | abinScience |
| Host species | Chimeric |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Purity | >95% as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | IgG1-kappa |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Endotoxin level | Please contact with the lab for this information. |
| Expression system | Mammalian Cells |
| Accession | P15391 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternative name | SAR3419, 1269764-99-9 |
| Species | Human |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Research Grade Coltuximab
Overview
Description
Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.
Images
 Bioactivity |
SEC-HPLC detection for Research Grade Coltuximab. |